Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Chief Medical Officer | September 25, 2023 | September 26, 2023 |
| LISATA THERAPEUTICS, INC.CLBS · Entity 7814 | Director | January 10, 2022 | January 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date September 25, 2023 · Filed September 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 451,826 |
Reported balance
After 2023-09-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-25 · Sale · Disposed 705 · Balance 451,826 F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2: Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2022 and February 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
F2: Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2022 and February 28, 2023.
LISATA THERAPEUTICS, INC.
Report date January 10, 2022 · Filed January 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 149,190 |
Reported balance
After 2022-01-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-10 · Grant · Acquired 65,430 · Balance 149,190 F1: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2: Includes 103,165 unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023.
F2: Includes 103,165 unvested restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GALECTIN THERAPEUTICS INC
Report date June 13, 2018 · Filed June 15, 2018
Section 16 reporting ended · disclosed 2018-06-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,333 |
Ending reported balance
After 2018-06-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-06-13 · Exercise / conversion · Acquired 100,000 · Balance 207,333 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Row 2 · 2018-06-13 · Sale · Disposed 100,000 · Balance 107,333 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F3: The shares were sold in multiple transactions at prices ranging from $7.00 to $8.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2026-12-03 | Direct | 50,000 |
Reported balance
After 2018-06-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-13 · Exercise / conversion · Disposed 100,000 · Balance 50,000 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F2: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018.
F2: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017.
F3: The shares were sold in multiple transactions at prices ranging from $7.00 to $8.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 25, 2023 Filed Sep 26, 2023 22:00 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 705 | $1.06 | $747.30 |
DisclosureSEC source: 0001453687-23-000067 · wk-form4_1695765617.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,826 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · balance_after: Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2022 and February 28, 2023. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 20 | $1.11 | $22.23 |
DisclosureSEC source: 0001453687-23-000032 · wf-form4_167304330841657.xml · nonDerivative · entry 4 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,121 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,445 | $1.13 | $3,890.44 |
DisclosureSEC source: 0001453687-23-000032 · wf-form4_167304330841657.xml · nonDerivative · entry 3 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,141 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 15 | $1.14 | $17.13 |
DisclosureSEC source: 0001453687-23-000032 · wf-form4_167304330841657.xml · nonDerivative · entry 2 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,586 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 8,164 | $1.13 | $9,255.53 |
DisclosureSEC source: 0001453687-23-000032 · wf-form4_167304330841657.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,601 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:59 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 900,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000015 · wf-form4_167286949656390.xml · derivative · entry 2 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2033-01-01 F3 · derivative.exercise_date: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:59 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000015 · wf-form4_167286949656390.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,765 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027. F2 · balance_after: Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between March 1, 2022 and August 31, 2022. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:15 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 65,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001284500-22-000003 · wf-form4_164202210716166.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,190 F1 · shares: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2 · balance_after: Includes 103,165 unvested restricted stock units. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 21:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,226 | $3.09 | $9,955.11 |
DisclosureSEC source: 0001453687-22-000034 · wf-form4_164159030863488.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,355 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.99 to $3.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:36 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 415,900 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001453687-22-000025 · wf-form4_164141856949283.xml · derivative · entry 2 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,900 Underlying: Common Stock · 415,900 shares Expires 2032-01-02 F2 · derivative.exercise_date: This option vests as to 25% on January 3, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:36 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 90,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000025 · wf-form4_164141856949283.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,581 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 3, 2023. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 3, 2026. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 22:17 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,083 | $2.99 | $12,195.51 |
DisclosureSEC source: 0001453687-21-000186 · wf-form4_163952020317161.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,381 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.94 to $3.0201. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000176 · wf-form4_163917405252050.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,464 F1 · kind: On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 27,500 shares of the Issuer's common stock (the "Performance RSUs"), which were earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. The compensation committee of the board of directors of the Issuer has determined that the second of the performance conditions has been met, and accordingly 13,750 Performance RSUs vested on December 8, 2021, Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 22:08 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,636 | $4.39 | $15,962.04 |
DisclosureSEC source: 0001453687-21-000144 · wf-form4_163433566388493.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,714 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.35 to $4.475. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:26 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000135 · wf-form4_163346558417377.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,350 F1 · kind: On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 27,500 shares of the Issuer's common stock (the "Performance RSUs"), which may be earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. Any Performance RSUs will generally vest in two equal installments upon the dates of achievement of each of the two performance conditions, subject to continued employment, so long as each performance condition is met before December 31, 2021. The compensation committee of the board of directors of the Issuer has determined that the first of the performance conditions has been met, and accordingly 13,750 Performance RSUs vested on October 1, 2021. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 20:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 54,400 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001453687-21-000121 · wf-form4_163286112666853.xml · derivative · entry 2 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,400 Underlying: Common Stock · 54,400 shares Expires 2031-09-23 F2 · derivative.exercise_date: This option vests as to 25% on September 24, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 20:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000121 · wf-form4_163286112666853.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,600 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on September 24, 2022. The remainder of the underlying shares will vest in three equalannual installments thereafter so that the underlying shares will be fully vested on September 24, 2025. Read SEC document |
| May 26, 2021 Filed May 27, 2021 22:00 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 20,000 | $3.99 | $79,850.00 |
DisclosureSEC source: 0001453687-21-000078 · wf-form4_162215281637006.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,500 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $3.959 to $4.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:33 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 5,000 | $3.48 | $17,400.00 |
DisclosureSEC source: 0001453687-21-000074 · wf-form4_162206119370229.xml · nonDerivative · entry 2 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,500 Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:33 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 12,500 | $3.32 | $41,497.50 |
DisclosureSEC source: 0001453687-21-000074 · wf-form4_162206119370229.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,500 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $3.315 to $3.32. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:34 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 10,000 | $4.50 | $45,000.00 |
DisclosureSEC source: 0001453687-21-000035 · wf-form4_161618965117089.xml · nonDerivative · entry 2 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 21:34 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 10,000 | $4.53 | $45,295.00 |
DisclosureSEC source: 0001453687-21-000035 · wf-form4_161618965117089.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.525 to $4.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:21 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 37,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001284500-21-000003 · wf-form4_161049368350061.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,760 F1 · shares: Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022. F2 · balance_after: Includes 56,027 unvested restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:50 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001453687-21-000018 · wf-form4_160996981436015.xml · derivative · entry 2 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2031-01-03 F2 · derivative.exercise_date: This option vests as to 25% on January 4, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:50 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000018 · wf-form4_160996981436015.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 4, 2022. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 4, 2025. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:31 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 40,000 | $3.24 | $129,424.00 |
DisclosureSEC source: 0001453687-20-000133 · wf-form4_160815426408163.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $3.165 to $3.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 20:36 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 650,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001453687-20-000090 · wf-form4_159657328133721.xml · derivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2030-07-31 F1 · derivative.exercise_date: This option will vest as to 25% on August 1, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 13, 2020 Filed Jan 14, 2020 21:19 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 18,292 | $3.28 | $59,997.76 |
DisclosureSEC source: 0001284500-20-000002 · wf-form4_157903675526265.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,025 F1 · shares: Represents 18,292 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 13, 2021. F2 · balance_after: Includes 18,292 unvested restricted stock units. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:13 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 12,121 | $4.95 | $59,998.95 |
DisclosureSEC source: 0001284500-19-000009 · wf-form4_154767318336251.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,733 F1 · shares: Represents 12,121 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 14, 2020. F2 · balance_after: Includes 12,121 unvested restricted stock units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 17:28 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 8,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001284500-19-000006 · wf-form4_154714127155595.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,612 F1 · shares: Represents 8,747 shares underlying restricted stock granted under the 2018 Equity Incentive Compensation Plan which were awarded on January 8, 2018 and which vested on January 8, 2019. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000054 · edgar.xml · derivative · entry 3 TRABER PETER G · CIK 0001284500 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 100,000 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F2 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 100,000 | $7.51 | $751,000.00 |
DisclosureSEC source: 0001179022-18-000054 · edgar.xml · nonDerivative · entry 2 TRABER PETER G · CIK 0001284500 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,333 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F3 · price: The shares were sold in multiple transactions at prices ranging from $7.00 to $8.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 100,000 | $0.87 | $87,000.00 |
DisclosureSEC source: 0001179022-18-000054 · edgar.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000050 · edgar.xml · derivative · entry 3 TRABER PETER G · CIK 0001284500 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 70,000 shares Expires 2026-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F2 · derivative.exercise_date: The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 70,000 | $5.86 | $409,997.00 |
DisclosureSEC source: 0001179022-18-000050 · edgar.xml · nonDerivative · entry 2 TRABER PETER G · CIK 0001284500 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,333 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. F3 · price: The shares were sold in multiple transactions at prices ranging from $5.50 to $6.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:51 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 70,000 | $0.87 | $60,900.00 |
DisclosureSEC source: 0001179022-18-000050 · edgar.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 125,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001179022-18-000039 · edgar.xml · derivative · entry 1 TRABER PETER G · CIK 0001284500 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: The options vest as follows: 25% on June 30, 2018, 25% on September30, 2018, and 50% on December 31, 2018. Read SEC document |
| January 15, 2018 Filed Jan 17, 2018 21:34 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 125,000 | $0.00 Strike: $5.87 | $0.00 |
DisclosureSEC source: 0001179022-18-000010 · edgar.xml · derivative · entry 1 TRABER PETER G · CIK 0001284500 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-01-15 F1 · derivative.exercise_date: The options vest as follows: 25% immediately, 25% on June 30, 2018, and 50% on December 31, 2018. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 21:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units · Derivative | 8,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-001693 · tv483048_4.xml · derivative · entry 1 TRABER PETER G · CIK 0001284500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,747 Underlying: Common Stock · 8,747 shares Expires 2028-01-08 F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the date that is one year from the date of grant. Read SEC document |
| May 16, 2017 Filed May 18, 2017 21:00 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 2,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-028454 · v467409_4.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,865 F1 · shares: Represents an award of 2,565 Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · balance_after: Includes 750 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on June 22, 2017, 1,650 shares of unvested restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018, 2,565 shares of unvested Restricted Stock Units granted under the Issuer's 2015 Equity Compensation Plan that will vest on May 16, 2018 and 312 shares of unvested restricted stock granted under the Issuer's 2009 Equity Compensation Plan that will vest quarterly through June 2, 2018. Read SEC document |
| January 09, 2017 Filed Jan 31, 2017 23:51 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantOptions to Purchase Common Stock · Derivative | 2,750 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001144204-17-005184 · v458003_4.xml · derivative · entry 2 TRABER PETER G · CIK 0001284500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2027-01-09 Read SEC document |
| January 09, 2017 Filed Jan 31, 2017 23:51 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-005184 · v458003_4.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 F1 · shares: Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018. F2 · balance_after: Includes 2,775 shares of unvested restricted stock granted under the Issuer's compensation plans. Read SEC document |
| December 03, 2016 Filed Dec 6, 2016 22:10 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 220,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001179022-16-000123 · edgar.xml · derivative · entry 1 TRABER PETER G · CIK 0001284500 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2026-12-03 F1 · derivative.exercise_date: The options vest as follows: 25% immediately, 25% on July 1, 2017, and 50% on December 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.